Profile
| Metric | Value |
|---|---|
| Full Name | Day One Biopharmaceuticals, Inc. |
| Ticker | NASDAQ: DAWN |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | dayonebio.com |
| Employees | 181 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $8.64 | |
| Price, 1D Change | +1.05% | |
| Market Cap | $887M | |
| - | ||
| PE Ratio | - | |
| Beta | 1.15 | |
| Revenue | $131M | |
| Revenue, 1Y Change | +100.00% | |
| EPS | -$1.02 | |
| EPS, 1Y Change | +56.75% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$1.02 | |
| EPS Estimate | -$0.97 | |
| EPS Est. Change | +5.04% | |
| Revenue | $131.16M | |
| Revenue Estimate | $148.51M | |
| Revenue Est. Change | +13.23% | |
| Current Price | $8.64 | |
| Price Target | - | $22.50 |
| Price Tgt. Change | - | +160.42% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.32 | -$2.37 | -2.08% | |
| -$0.67 | -$1.02 | -52.61% | |
| -$0.97 | N/A | +5.04% | |
| -$0.65 | N/A | +36.73% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $0.00 | - | |
| $122.52M | $131.16M | +7.05% | |
| $148.51M | N/A | +13.23% | |
| $222.81M | N/A | +69.88% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -29.18% | |
| Price, 3Y | -59.51% | |
| Market Cap, 1Y | -28.09% | |
| Market Cap, 3Y | -43.41% | |
| Revenue, 1Y | +100.00% | |
| Revenue, 3Y | +100.00% | |
| EPS, 1Y | +56.75% | |
| EPS, 3Y | +62.81% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $8.64 | |
| SMA 200 | $7.42 | |
| SMA 200 vs Price | -14.08% | |
| SMA 50 | $8.71 | |
| SMA 50 vs Price | +0.76% | |
| Beta | 1.15 | |
| ATR | $0.52 | |
| 14-Day RSI | 46.38 | |
| 10-Day Volatility | 39.86% | |
| 1-Year Volatility | 68.91% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $131.16M | |
| EPS | -$1.02 | |
| Gross Profit | $125.88M | |
| Gross Margin | 95.98% | |
| Operating Profit | -$217.27M | |
| Operating Margin | -165.65% | |
| Net Income | -$95.50M | |
| Net Margin | -72.81% | |
| EBITDA | -$215.24M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.01 | |
| 7.66 | ||
| 7.61 | ||
| - | ||
| 2 | ||
| 5.32 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 6.64 | ||
| 1.97 | ||
| -2.71 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $502.75M | |
| $124.97M | ||
| $582.79M | ||
| $562.33M | ||
| $80.04M | ||
| $73.45M | ||
| Total Debt | $2.60M | |
| $10.00K | ||
| $3.26M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $348.43M | ||
| $343.15M | ||
| $5.28M | ||
| $115.45M | ||
| $2.03M | ||
| $0.00 | ||
| $7.14M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$78.11M | ||
| -$230.99M | ||
| $203.29M | ||
| Capex | $19.27M | |
| -$152.38M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Needham | → | |
| HC Wainwright & Co. | → | |
| JP Morgan | → | |
| Piper Sandler | → | |
| Needham | → | |
| HC Wainwright & Co. | → | |
| Needham | → | |
| HC Wainwright & Co. | → | |
| Goldman Sachs | → | |
| JP Morgan | → |
Analyst sentiment
Institutional ownership
Screeners with DAWN
Data Sources & References
- DAWN Official Website dayonebio.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1845337/000119312525264649/0001193125-25-264649-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1845337/000095017025026654/0000950170-25-026654-index.htm
- DAWN Profile on Yahoo Finance finance.yahoo.com/quote/DAWN
- DAWN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/dawn
FAQ
What is the ticker symbol for Day One Biopharmaceuticals, Inc.?
The ticker symbol for Day One Biopharmaceuticals, Inc. is NASDAQ:DAWN
Does Day One Biopharmaceuticals, Inc. pay dividends?
No, Day One Biopharmaceuticals, Inc. does not pay dividends
What sector is Day One Biopharmaceuticals, Inc. in?
Day One Biopharmaceuticals, Inc. is in the Healthcare sector
What industry is Day One Biopharmaceuticals, Inc. in?
Day One Biopharmaceuticals, Inc. is in the Biotechnology industry
What country is Day One Biopharmaceuticals, Inc. based in?
Day One Biopharmaceuticals, Inc. is headquartered in United States
When did Day One Biopharmaceuticals, Inc. go public?
Day One Biopharmaceuticals, Inc. initial public offering (IPO) was on May 27, 2021
Is Day One Biopharmaceuticals, Inc. in the S&P 500?
No, Day One Biopharmaceuticals, Inc. is not included in the S&P 500 index
Is Day One Biopharmaceuticals, Inc. in the NASDAQ 100?
No, Day One Biopharmaceuticals, Inc. is not included in the NASDAQ 100 index
Is Day One Biopharmaceuticals, Inc. in the Dow Jones?
No, Day One Biopharmaceuticals, Inc. is not included in the Dow Jones index
When was Day One Biopharmaceuticals, Inc. last earnings report?
Day One Biopharmaceuticals, Inc.'s most recent earnings report was on November 4, 2025
When does Day One Biopharmaceuticals, Inc. report earnings?
The next expected earnings date for Day One Biopharmaceuticals, Inc. is February 24, 2026